Ocular Therapeutix, Inc. (OCUL) shares climbed 9.24%, trading at $9.34, up $0.79, after the company reported fourth-quarter and full-year 2025 financial results that showed mixed revenue performance and highlighted ongoing clinical investment.
The company said its Q4 2025 net revenue was $13.3 million, down from $17.1 million a year earlier, and full-year 2025 net revenue totaled $52.0 million, declining from $63.7 million in 2024.
The results reflected decreases in product and collaboration revenue alongside increased research and development and operating expenses tied to clinical programs. Ocular Therapeutix reported a net loss of $64.7 million, or $0.29 loss per share, for the quarter.
On the day of the release, OCUL opened near $8.9, traded up to an intraday high around $9.75, and saw a low near $8.65, compared with its previous close of $8.55. Trading volume reflected increased investor focus on the earnings report and future clinical catalysts.
Ocular Therapeutix's 52-week range of approximately $5.78 to $16.44 underscores the biotech's volatility amid fluctuating revenue trends and clinical progress. Despite the revenue decline and quarterly loss, Ocular Therapeutix highlighted upcoming trial data and pipeline milestones, supporting investor interest in the company's long-term strategic direction.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.